Drug Trial Radar · NCT06162572
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
102
Actual
Start
Aug 7, 2024
Primary completion
Apr 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Servier Bio-Innovation LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Institut de Recherches Internationales Servier; Regeneron Pharmaceuticals
- First posted
- Dec 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
S095018Drug
Via IV infusion on Day 1 of each 21-day cycle
S095024Drug
Via IV infusion on Day 1 of each 21-day cycle
S095029Drug
Via IV infusion on Day 1 of each 21-day cycle
S095018 Recommended Dose Expansion (RDE)Drug
Via IV infusion on Day 1 of each 21-day cycle
S095024 RDEDrug
Via IV infusion on Day 1 of each 21-day cycle
S095029 RDEDrug
Via IV infusion on Day 1 of each 21-day cycle
CemiplimabDrug
350 mg via IV infusion on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of dose-limiting toxicities (DLTs) during the first 2 cycles of combination treatmentTime frame: Through the end of the Cycle 2 (each cycle is 21 days)
- Incidence and severity of adverse events (AEs)Time frame: From the signed informed consent form (ICF) to 30 days after the last dose
- Incidence and severity of serious adverse events (SAEs)Time frame: From the signed ICF to 120 days after the last dose
- Adverse Events (AEs) Leading to Dose Interruption, Modification, or DelaysTime frame: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
- Adverse Events (AEs) Leading to Permanent Treatment DiscontinuationTime frame: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
- Objective Response (OR)Time frame: Until study termination (approximately 2 years)
Locations
51 sites in 13 countries. Site status is shown where the registry gives one.
Henry Ford Health
Detroit, Michigan
Gabrail Cancer Center
Canton, Ohio
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Border Medical Oncology Research Unit
Albury, Australia
Flinders Medical Centre
Bedford Park, Australia
Sunshine Hospital
St Albans, Australia
Latrobe Regional Health
Traralgon, Australia
Universitatsklinikum St. Poelten
Sankt Pölten, Austria
Medical University of Vienna - Akh
Vienna, Austria
Jessa Ziekenhuis
Hasselt, Belgium
Hospital de Amor - Barretos
Barretos, Brazil
Supera Oncologia
Chapecó, Brazil
CIONC
Curitiba, Brazil
Liga Contra O Cancer - Natal
Natal, Brazil
Santa Casa de Porto Alegre
Porto Alegre, Brazil
Hospital São Lucas Da Pucrs
Porto Alegre, Brazil
Oncoclinicas Rj
Rio de Janeiro, Brazil
Hospital A C Camargo
São Paulo, Brazil
Hospital São Camilo
São Paulo, Brazil
Oncoclinicas Sp
São Paulo, Brazil
Hospital Albert Einstein
São Paulo, Brazil
Centre Georges Francois Leclerc
Dijon, France
Chu Grenoble Alpes
Grenoble, France
Institut Paoli Calmette
Marseille, France
Centre René Gauducheau/Inst de Cancér. de L'Ouest
Saint-Herblain, France
Institut Gustave Roussy
Villejuif, France
Queen Mary Hospital
Hong Kong, Hong Kong
Farkasgyepu Tudogyogyintezet
Farkasgyepű, Hungary
Bugat Pal Hospital
Gyöngyös, Hungary
Pecsi Tudomanyegyetem, Klinikai Kozpont
Pécs, Hungary
Centro Di Riferimento Oncologico
Aviano, Italy
Inst. Romagnolo Per Lo Studio E La Cura Dei Tumori
Meldola, Italy
Irccs Fondazione Istituto Nazionale Dei Tumori
Milan, Italy
Istituto Europeo Di Oncologia
Milan, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
Ist. Nazionale Tumori Irccs Fondazione G Pascale
Naples, Italy
Azienda Ospedaliera S. Maria Della Misericordia
Perugia, Italy
Istituto Nazionale Tumori Regina Elena
Roma, Italy
Istituto Clinico Humanitas I.R.C.C.S
Rozzano, Italy
Inst Oncologic "Prof Dr I Chiricuta" Cluj Napoca
Cluj-Napoca, Romania
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.